The European Medicines Agency has carried out a consultation on increased transparency and access to information included in companies' applications for marketing authorization. In its response submitted yesterday, EFPIA, the voice of the research-based pharmaceutical industry, expressed support for the release of almost all clinical data. "For several years my members have shared summary results for all clinical trials involving patients. Now is the time to take another step towards full transparency,” says Richard Bergström, Director General of EFPIA.
"There will be details on patients and individuals that need to be protected, but beyond that I think all clinical test results should be disclosed as soon as a new medicine is approved. The real challenge now is to find practical ways to make this data useful. No one will benefit from a "data dump." Industry and regulators must work with patient groups to make sure that data is provided in a way that is helpful for patients and relatives. New tools are needed to help users navigate and understand the vast amount of data that will be released. In particular the concept of benefit-risk needs to be clearly explained so that everyone who is interested can understand the reasons for approving a particular medicine," says Richard Bergström.
"The role of medical journals will also change: they will be more important than ever to summarize and explain research findings. But they must also adapt to the fact that key data may be disclosed by regulators before they are published in a journal. We must all adapt to the new era of full transparency," Richard Bergström concluded.
The submission of EFPIA comments on Draft HMA/EMA guidance document on the identification of CCI and PPD with the structure of the MA dossier is available for download here: http://www.efpia.eu/Content/Default.asp?PageID=559&DocID=11908.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.